BioMarin Pharmaceutical to acquire Amicus Therapeutics for $4.8B
BioMarin Pharmaceutical (NASDAQ:BMRN) and Amicus Therapeutics (NASDAQ:FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction.
The total equity value of the transaction is approximately $4.8 billion.
The agreement has been unanimously approved by the Boards of Directors of both companies, and Amicus' Board of Directors has unanimously recommended that its stockholders vote to adopt the agreement.
The acquisition is expected to close in the second quarter of 2026, subject to regulatory clearances, approval by Amicus' stockholders, and other customary closing conditions.
This acquisition strengthens BioMarin’s position in the pharmaceutical industry and expands its portfolio in rare disease therapies, reinforcing its commitment to delivering life-changing treatments to patients.
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
